The idea that PERK can behave as an oncogene is in keeping with the more aggressive phenotype associated with PERK over-expression in multiple cancers27–30, as well as the anti-tumour effects of PERK inhibition in myeloma cells31. This evidence concerns the gene EIF2AK3 and plasma cell myeloma.